• Je něco špatně v tomto záznamu ?

Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine

CWE. Embregts, D. Rigaudeau, L. Tacchi, GP. Pijlman, L. Kampers, T. Veselý, D. Pokorová, P. Boudinot, GF. Wiegertjes, M. Forlenza,

. 2019 ; 85 (-) : 66-77. [pub] 20180319

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028513

We recently reported on a successful vaccine for carp against SVCV based on the intramuscular injection of a DNA plasmid encoding the SVCV glycoprotein (SVCV-G). This shows that the intramuscular (i.m.) route of vaccination is suitable to trigger protective responses against SVCV, and that the SVCV G-protein is a suitable vaccine antigen. Yet, despite the general success of DNA vaccines, especially against fish rhabdoviruses, their practical implementation still faces legislative as well as consumer's acceptance concerns. Furthermore, the i.m. route of plasmid administration is not easily combined with most of the current vaccination regimes largely based on intraperitoneal or immersion vaccination. For this reason, in the current study we evaluated possible alternatives to a DNA-based i.m. injectable vaccine using the SVCV-G protein as the vaccine antigen. To this end, we tested two parallel approaches: the first based on the optimization of an alginate encapsulation method for oral delivery of DNA and protein antigens; the second based on the baculovirus recombinant expression of transmembrane SVCV-G protein in insect cells, administered as whole-cell subunit vaccine through the oral and injection route. In addition, in the case of the oral DNA vaccine, we also investigated the potential benefits of the mucosal adjuvants Escherichia coli lymphotoxin subunit B (LTB). Despite the use of various vaccine types, doses, regimes, and administration routes, no protection was observed, contrary to the full protection obtained with our reference i.m. DNA vaccine. The limited protection observed under the various conditions used in this study, the nature of the host, of the pathogen, the type of vaccine and encapsulation method, will therefore be discussed in details to provide an outlook for future vaccination strategies against SVCV.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028513
003      
CZ-PrNML
005      
20190820092547.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.fsi.2018.03.028 $2 doi
035    __
$a (PubMed)29567136
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Embregts, C W E $u Cell Biology and Immunology Group, Wageningen University, The Netherlands.
245    10
$a Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine / $c CWE. Embregts, D. Rigaudeau, L. Tacchi, GP. Pijlman, L. Kampers, T. Veselý, D. Pokorová, P. Boudinot, GF. Wiegertjes, M. Forlenza,
520    9_
$a We recently reported on a successful vaccine for carp against SVCV based on the intramuscular injection of a DNA plasmid encoding the SVCV glycoprotein (SVCV-G). This shows that the intramuscular (i.m.) route of vaccination is suitable to trigger protective responses against SVCV, and that the SVCV G-protein is a suitable vaccine antigen. Yet, despite the general success of DNA vaccines, especially against fish rhabdoviruses, their practical implementation still faces legislative as well as consumer's acceptance concerns. Furthermore, the i.m. route of plasmid administration is not easily combined with most of the current vaccination regimes largely based on intraperitoneal or immersion vaccination. For this reason, in the current study we evaluated possible alternatives to a DNA-based i.m. injectable vaccine using the SVCV-G protein as the vaccine antigen. To this end, we tested two parallel approaches: the first based on the optimization of an alginate encapsulation method for oral delivery of DNA and protein antigens; the second based on the baculovirus recombinant expression of transmembrane SVCV-G protein in insect cells, administered as whole-cell subunit vaccine through the oral and injection route. In addition, in the case of the oral DNA vaccine, we also investigated the potential benefits of the mucosal adjuvants Escherichia coli lymphotoxin subunit B (LTB). Despite the use of various vaccine types, doses, regimes, and administration routes, no protection was observed, contrary to the full protection obtained with our reference i.m. DNA vaccine. The limited protection observed under the various conditions used in this study, the nature of the host, of the pathogen, the type of vaccine and encapsulation method, will therefore be discussed in details to provide an outlook for future vaccination strategies against SVCV.
650    _2
$a zvířata $7 D000818
650    12
$a kapři $7 D002347
650    _2
$a nemoci ryb $x imunologie $x prevence a kontrola $x virologie $7 D005393
650    _2
$a Rhabdoviridae $x imunologie $7 D012209
650    _2
$a infekce viry z čeledi Rhabdoviridae $x imunologie $x prevence a kontrola $x veterinární $x virologie $7 D018353
650    _2
$a Sf9 buňky $7 D061987
650    _2
$a Spodoptera $7 D018411
650    _2
$a vakcinace $x veterinární $7 D014611
650    _2
$a DNA vakcíny $x aplikace a dávkování $x klasifikace $x farmakologie $7 D019444
650    _2
$a subjednotkové vakcíny $x aplikace a dávkování $x klasifikace $x farmakologie $7 D022223
650    _2
$a virové vakcíny $x aplikace a dávkování $x klasifikace $x farmakologie $7 D014765
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rigaudeau, D $u INRA, Infectiologie Expérimentale Rongeurs Poissons, Université Paris-Saclay, Jouy-en-Josas, France.
700    1_
$a Tacchi, L $u Cell Biology and Immunology Group, Wageningen University, The Netherlands.
700    1_
$a Pijlman, G P $u Laboratory of Virology, Wageningen University, The Netherlands.
700    1_
$a Kampers, L $u Cell Biology and Immunology Group, Wageningen University, The Netherlands; Laboratory of Virology, Wageningen University, The Netherlands.
700    1_
$a Veselý, T $u Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Pokorová, D $u Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Boudinot, P $u INRA, Virologie et Immunologie Moléculaires, Université Paris-Saclay, Jouy-en-Josas, France.
700    1_
$a Wiegertjes, G F $u Cell Biology and Immunology Group, Wageningen University, The Netherlands.
700    1_
$a Forlenza, M $u Cell Biology and Immunology Group, Wageningen University, The Netherlands. Electronic address: maria.forlenza@wur.nl.
773    0_
$w MED00184791 $t Fish & shellfish immunology $x 1095-9947 $g Roč. 85, č. - (2019), s. 66-77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29567136 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190820092822 $b ABA008
999    __
$a ok $b bmc $g 1433662 $s 1066973
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 85 $c - $d 66-77 $e 20180319 $i 1095-9947 $m Fish & shellfish immunology $n Fish Shellfish Immunol $x MED00184791
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace